Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures: 2017-2025

Historic Gains from Sales and Divestitures for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Sep 2025 value amounting to $152,000.

  • Enanta Pharmaceuticals' Gains from Sales and Divestitures rose 24.59% to $152,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $152,000, marking a year-over-year increase of 24.59%. This contributed to the annual value of $152,000 for FY2025, which is 24.59% up from last year.
  • Enanta Pharmaceuticals' Gains from Sales and Divestitures amounted to $152,000 in FY2025, which was up 24.59% from $122,000 recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Gains from Sales and Divestitures registered a high of $152,000 during FY2025, and its lowest value of $29,000 during FY2022.
  • For the 3-year period, Enanta Pharmaceuticals' Gains from Sales and Divestitures averaged around $114,667, with its median value being $122,000 (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Gains from Sales and Divestitures plummeted by 35.56% in 2022, and later soared by 141.38% in 2023.
  • Enanta Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $45,000 in 2021, then tumbled by 35.56% to $29,000 in 2022, then surged by 141.38% to $70,000 in 2023, then surged by 74.29% to $122,000 in 2024, then grew by 24.59% to $152,000 in 2025.